Raynaud's phenomenon (RP) is present in more than 95% of patients with systemic
sclerosis (SSc). Its frequency and severity in combination with the presence of digital ulcers …

Rheumatology Vol. 43 No. 11 ß British Society for Rheumatology 2004; all rights reserved
hypertension [pulmonary artery pressure (PAP) ¼ 46 mmHg] with tricuspid insufficiency …

Objective. To investigate the efficacy of the endothelin receptor antagonist, bosentan, in
patients with RP secondary to SSc without pre-existing digital ulcers. Methods. Single …

SIR, In recent years, endothelin (ET)-1 has been strongly implicated in the pathogenesis of
systemic sclerosis (SSc)[1] and it has recently been shown that the ET-1 receptor antagonist …

Secondary Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc) and other
collagen vascular diseases is a serious manifestation of microvascular damage that may …

4. O'Connor BL, Palmoski MJ, Brandt KD. Neurogenic acceleration of degenerative joint
lesions. J Bone Joint Surg 1985; 67A: 562–72. 5. Yamamoto T, Bullough PG. The role of …

The objective of this study was to evaluate the efficacy of the endothelin receptor antagonist,
bosentan, in patients with Raynaud's phenomenon secondary to systemic sclerosis never …

METHODS AND RESULTS We performed a retrospective chart review of 10 patients with
SSc seen at a tertiary care referral centre who were offered sildenafil after standard …

SIR, SSc is characterized by fibrotic thickening of the skin and internal organs and
widespread vascular damage [1]. The first vascular event is RP and digital ulcers (DUs) are …

SIR, Raynaud's phenomenon is characterized by recurrent episodes of vasospasm most
commonly occurring in the hands and feet. It is a manifestation of the widespread vascular …